Protocol Ledger

NCT03773965 · Phase III · RECRUITING

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

Interventional Phase III clinical trial protocol NCT03773965 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-04-05 Enrollment: 190 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03773965
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)190 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03773965
Protocol FieldVerified Registry Value
NCT IdentifierNCT03773965
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment190 participants (ESTIMATED)
Registered Start Date2019-04-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03773965
Hospital Research SiteLocationSite Profile
The Children's Hospital at WestmeadWestmead, AustraliaOpen Hospital Dossier ->
Cliniques Universitaires Saint-LucBrussels, BelgiumOpen Hospital Dossier ->
UZ GentGhent, BelgiumOpen Hospital Dossier ->
UZ LeuvenLeuven, BelgiumOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI